Showing results (81-90 of 95) with videos related to
Sort By:
Pageof 10
Leukemia|July 19, 2022
PARP14 is a novel target in STAT6 mutant follicular lymphomaMichael Mentz, William Keay, Carolin Dorothea Strobl, et al.Plos Medicine|December 14, 2016
Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution StudyRobert Kridel, Fong Chun Chan, Anja Mottok, et al.Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Relapse timing is associated with distinct evolutionary dynamics in DLBCLLaura K Hilton, Henry S Ngu, Brett Collinge, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell LymphomaDaisuke Ennishi, Aixiang Jiang, Merrill Boyle, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2023
Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell LymphomaLaura K Hilton, Henry S Ngu, Brett Collinge, et al.Science Translational Medicine|June 21, 2019
Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B cell lymphomaNeeraj Jain, Keenan Hartert, Saber Tadros, et al.Blood Cancer Journal|August 7, 2024
Identification of genetic subtypes in follicular lymphomaVictoria Shelton, Rajesh Detroja, Ting Liu, et al.Blood Advances|October 2, 2019
Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma AllianceJoshua W D Tobin, Gabrielle Rule, Katherine Colvin, et al.The Lancet. Oncology|August 11, 2015
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registryAlessandro Pastore, Vindi Jurinovic, Robert Kridel, et al.Ebiomedicine|December 4, 2024
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphomaMichael P MacManus, John F Seymour, Hennes Tsang, et al.Pageof 10